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Anti-N-methyl-D-aspartate (NMDA) receptor encephalitis is an autoimmune disorder characterized by IgG autoantibodies
directed against the NR1 subunit of the NMDA glutamate receptor. Psychiatric symptoms are common and include psychosis,
mania, depressed mood, aggression, and speech abnormalities. Neurological symptoms such as seizures, decreased responsiveness,
dyskinesias, and other movement abnormalities and/or autonomic instability are frequently seen as well. We present the case of a
woman who was followed up at our facility for over 14 years for the treatment of multiple neuropsychiatric symptoms. Initially, she
presented with paresthesias, memory loss, and manic symptoms. Nine years later, she presented to our facility again, this time with
left sided numbness, left eyelid droop, and word finding difficulties. Finally, five years later, she presented with manic symptoms,
hallucinations, and memory impairment. During her hospitalization, she subsequently developed catatonic symptoms and seizures.
During her stay, it was discovered that she was positive for anti-NMDA receptor antibodies and her symptoms responded well to
appropriate therapy. This case demonstrates that it may be useful for clinicians to consider screening for anti-NMDA receptor
antibodies in long-term patients with neuropsychiatric symptoms that have not adequately responded to therapy.

1. Introduction
Anti-N-methyl-D-aspartate (NMDA) receptor encephalitis is
an autoimmune disorder characterized by IgG autoantibodies
directed against the NR1 subunit of the NMDA glutamate
receptor. The disease commonly occurs in young females
and frequently is associated with ovarian teratoma, but
cases have been reported in males and females of all ages
(8 months to 85 years), with or without teratoma [1, 2].
The majority of patients experience prodromal symptoms,
including headache, fever, nausea, vomiting, diarrhea, or
upper respiratory-tract symptoms. Within a few days, and
typically fewer than two weeks, patients exhibit psychiatric
and cognitive abnormalities which progress to seizures in the

initial stage of the disorder. This is often followed days to
weeks later by decreased responsiveness that may alternate
between periods of agitation and catatonia, associated with
neurological findings including dyskinesias (especially orofacial) and other abnormal movements (e.g., limb and trunk
choreoathetosis, elaborate motions of the arms and legs, oculogyric crisis, and spastic rigidity). Patients simultaneously
develop autonomic instability, characterized most frequently
by hyperthermia, tachycardia, hypersalivation, hypertension,
bradycardia, hypotension, urinary incontinence, and erectile
dysfunction. Cardiac dysrhythmias and hypoventilation may
ensue, necessitating pacemaker placement or intubation and
mechanical ventilation [1, 3].
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In the initial phase of the disorder, patients may present
with a number of psychiatric findings, including anxiety,
insomnia, confusion, psychosis (delusions and/or auditory or
visual hallucinations), mania, depressed mood, aggression,
short-term memory loss, emotional disturbances, and speech
abnormalities (e.g., reduced verbal output, frank mutism,
and echolalia) [1, 2, 4]. While these signs and symptoms
may be accompanied by the florid neurological deterioration
described above, milder or incomplete forms of anti-NMDA
receptor encephalitis have been observed in a subset of
patients (4% in a recent cohort of 571 patients with IgG
antibodies against the NR1 subunit of the NMDA receptor),
with apparently isolated psychiatric symptoms, seizures, or
dystonia [1, 4]. These patients do not necessarily progress to
severer disease despite prolonged periods without treatment
[4].
In this paper, we present the case of a patient who
experienced a severe, more typical manifestation of antiNMDA receptor encephalitis following a history of previous
psychosis and neurological abnormalities.

2. Case Presentation
The patient was a mixed-race female (father Caucasian,
mother East Asian) who presented to our facility at the age
of 24 with disorganized thinking, increased energy, increased
appetite, increased libido, labile mood, and abnormal sleep
patterns. In the six months prior to this episode, she had
visited the outpatient neurology clinic on several occasions
for bilateral upper extremity paresthesias and weakness.
During the initial interview at our facility, the patient
displayed marked word-finding difficulty and short-term
memory impairment. At the time, she was not receiving
treatment with any psychotropic medication. Head CT and
MRI of the brain were normal. EEG was interpreted as
showing mild, diffuse slowing. The patient was treated with
olanzapine 10 mg PO QD and valproic acid 250 mg PO
TID with improvement in manic symptoms, although two
weeks later at time of discharge she still appeared confused,
inappropriately answering multiple questions by stating, “I
feel fine, I feel fine.” She was discharged to a psychosocial
rehabilitation and recovery center (PRRC) with a diagnosis
of schizoaffective disorder, bipolar type.
Ten days later, the patient returned to our facility with
increased agitation, disorientation, impaired attention, auditory hallucinations of singing voices, left-sided paresthesias,
and a delusional belief that she was pregnant. Since being
discharged to the PRRC, the patient had become unable
to answer simple questions or follow simple directions. She
was admitted to our facility and stayed as an inpatient for
30 days, during which time she was given trials of several neuroleptics—including haloperidol 2 mg PO BID and
mesoridazine 50 mg PO BID—with minimal improvement in
her disorganized thinking. When she was discharged again
to the PRRC, the patient continued to display impaired
attention and was unable to perform serial 3s or spell
“world” backwards. During her stay at the rehab center, the
patient exhibited persistently disinhibited and hypersexual
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behavior for several months. She had to be prevented from
compulsively overeating and was noted to sneak away to eat
large amounts of ice cream out of a bucket. The patient did
recover gradually, however, and after a 4-month stay at the
rehab center had returned to her preillness baseline mental
status. She then maintained regular follow-up appointments
in our outpatient psychiatric clinic for supportive therapy and
medication management.
Nine years after the previously described hospitalization,
at the age of 33, the patient presented to our outpatient
psychiatric clinic with speech problems. For 2 weeks, she
had experienced word-finding difficulty, stating, “It’s like
my brain is not connected to my mouth.” In addition, she
reported intermittent left-sided eyelid drooping and left-face
and left-arm numbness, while denying any weakness. Her
only psychotropic medication at the time was lamotrigine
(maximum dose 200 mg PO QD) for mood stabilization.
On physical exam, she demonstrated left-sided ptosis with
continuous upward gaze; otherwise, her neurological exam
was without abnormalities. Brain MRI was normal. Serology to evaluate for myasthenia gravis was negative, and
EMG/NCS with repetitive stimulation was normal. Our
neurology service was consulted; given the lack of specific
findings suggestive of myasthenia gravis or cerebrovascular
accident, the patient was managed conservatively. At a followup visit five months later, her previous signs and symptoms
had resolved spontaneously. The patient then continued to
maintain regular follow-up with our outpatient psychiatry
clinic.
At the age of 38, the patient presented to our emergency
department with labile mood, confusion, agitation, easy
distractibility, and insomnia. For the previous one month,
she had experienced short-term memory impairment and
frequent auditory hallucinations of electronic dance music,
for which our outpatient psychiatry clinic had placed her
on aripiprazole 5 mg PO QD as well as increasing her dose
of lamotrigine from 200 mg to 250 mg PO QD, although
the memory problems and hallucinations had persisted. Her
only psychotropic medications at this time were lamotrigine
and aripiprazole (doses as above), and she reported strict
compliance. While being interviewed in the ED, the patient
exhibited both thought blocking and frequent word-finding
difficulty.
The patient was admitted to the inpatient psychiatric
ward with a diagnosis of “bipolar I disorder, mixed with psychotic features” and began to manifest catatonic symptoms,
including mutism, waxy flexibility, and posturing, alternating
with undirected motor agitation and yelling. Six weeks after
admission, she developed autonomic instability with fever
to 102∘ F and CPK > 18,000. Aripiprazole was discontinued
due to concern for neuroleptic malignant syndrome; despite
the absence of rigidity, dystonias, or leukocytosis, it was
determined that rhabdomyolysis in the setting of catatonia
was a more likely diagnosis. The patient’s lamotrigine was
also discontinued at this time, and once her CPK level had
returned to normal, she underwent three ECT treatments
for her refractory catatonia. Prior to the fourth scheduled
treatment, she experienced several generalized tonic-clonic
seizures and was transferred to the ICU and intubated. Video

Case Reports in Psychiatry
EEG confirmed the diagnosis of generalized tonic-clonic
seizures but was limited by significant muscle and movement
artifacts. However, based on the clinical semiology and
subtle electrographic features prior to generalization, the
seizures likely originated in the left frontal lobe. MRI brain
showed no abnormalities. Anti-NMDA receptor antibodies
were detected on serological testing, confirming a diagnosis
of anti-NMDA receptor encephalitis. Oncologic workup with
CT chest, CT abdomen/pelvis, and PET/CT from skull base
to mid-thigh was negative for any tumor or malignancy. The
patient received high dose IV corticosteroids (methylprednisolone 1 g/day) and IVIG (Gamunex 0.4 g/kg/day) for five
days with resolution of catatonia, although her cognition
remained impaired. She underwent a second course of high
dose IV corticosteroids (methylprednisolone 1 g/day) for
7 days with improvement in mental status, although she
continued to display memory impairment, slurred speech,
and impaired attention. The patient was discharged on
prednisone 60 mg PO QD (1 mg/kg) and continued treatment
as an outpatient. Her psychotropic medications at discharge
were clonazepam 2 mg PO QID for anxiety and valproic acid
500 mg PO BID for mood stabilization and seizure prophylaxis. Since that time, the patient gradually has been weaned
off of prednisone over the course of one year. She experienced
improvement in cognition over several months, and at a
follow-up visit in our clinic eight months after discharge
she was clearly at her premorbid level of cognitive function.
At her most recent outpatient clinic visit, one year after
discharge, the patient continued to be at her baseline level of
cognitive function with no return of psychiatric or neurologic
symptoms. At this time, her only psychotropic medication is
lamotrigine 100 mg PO QD for mood stabilization.

3. Discussion
A recent cohort study of 571 patients with IgG antibodies
targeting the NR1 subunit of the NMDA receptor found
that 23 (4%) of these patients developed isolated psychiatric
episodes (defined by the authors as lacking neurological
involvement), either at disease onset or relapse [4]. Some
of these episodes might be characterized more accurately as
limited forms of the disease rather than isolated psychiatric
episodes, as mild neurological abnormalities (e.g., orofacial
dyskinesias, memory problems, and hypersalivation) were
found on exam, along with abnormal but nonspecific findings
on EEG (either epileptic or nonspecific slowing) and MRI
(including nonspecific fluid-attenuated inversion recovery
changes involving temporal, frontal, and/or parietal lobes;
mild atrophy of temporal lobes; and diffusion-restricted
abnormality in the corpus callosum). Moreover, analysis
of the 571 patients in this study showed that those with
monosymptomatic or milder presentations do not necessarily progress to more severe multisymptom disease, despite
prolonged periods without treatment. The fact that the five
patients in this study who presented with limited forms of the
disorder at disease onset were tested for anti-NMDA receptor
antibodies only after abnormal findings were discovered on
MRI suggests that this condition might be underdiagnosed
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in patients without abnormal findings on ancillary testing
[4]. Moreover, the identification of this limited form of antiNMDA receptor encephalitis begs the question of what the
natural history of the disease would be if these patients are not
treated with immunotherapy and, when applicable, tumor
removal.
In the present case, our patient initially presented to our
facility at the age of 24 with psychosis, confusion, labile
mood, cognitive impairment, and paresthesias, with diffuse
slowing noted on EEG. During her recovery from this first
episode, she displayed persistent impairment in executive
function with impulsivity and disinhibition that resolved
over the course of several months. In retrospect, we propose
that given the subsequent detection of anti-NMDA receptor
antibodies during her presentation at the age of 38, her
earlier episodes may have represented limited presentations
of anti-NMDA receptor encephalitis. This possibility appears
more likely given that an EEG performed at the age of 28
for an isolated syncopal episode (the patient was otherwise
psychiatrically and neurologically asymptomatic at this time)
showed no abnormal slowing or other abnormal findings.
Several recent studies have shown that patients with a history
of psychosis associated with bipolar disorder, schizophrenia,
or schizoaffective disorder tend to display persistent EEG
abnormalities even when not actively psychotic [5, 6]. It
appears that EEG abnormalities in anti-NMDA receptor
encephalitis, on the other hand, tend to resolve with clinical
improvement [3, 7].
The obvious limitation of our hypothesis is that antiNMDA receptor antibodies were not tested, and therefore not
detected, in the patient until she presented with florid disease
at the age of 38. However, given the aggregate of less specific
findings (psychosis, confusion, memory impairment, dyskinesias, speech and language problems, impaired executive
function, and EEG abnormalities) from previous episodes
that collectively resist explanation by an alternative diagnosis,
we believe it is reasonable to suggest anti-NMDA receptor
encephalitis as a retrospective diagnosis that would account
for these findings.
This case is significant because, to our knowledge, if
our patient’s previous episodes are in fact attributable to
pathogenic anti-NMDA receptor antibodies, this would represent the most extensive illustration to date of the natural
history of the disease in a patient not initially treated
with immunotherapy or tumor removal, characterized by
relapsing and remitting symptoms subsequently progressing
to florid disease with seizures, dyskinesias, and autonomic
dysfunction, ultimately requiring intubation and mechanical
ventilation. Previous case series have described patients who
spontaneously recovered from the disease without receiving
immunotherapy or tumor removal and also patients who
have experienced multiple relapses of the disease after treatment [3, 8].
In terms of practical implications, we believe our patient’s
case supports the recommendations of others to test for antiNMDA receptor antibodies in cases of psychosis (both first
episode and recurrent) with neurological abnormalities (e.g.,
dyskinesias, speech and language problems) and/or abnormal
findings on ancillary testing (EEG, MRI) [4]. When our
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patient first presented to our facility at the age of 24 with
psychosis and neurological symptoms, anti-NMDA receptor
encephalitis had not yet been characterized as a clinical entity.
However, given that anti-NMDA receptor antibodies have
been found to remain detectable after recovery from the acute
illness, it is not unreasonable to suppose that our patient
might have tested positive for these antibodies had serology
been performed sometime between this initial hospitalization
and her final presentation at the age of 38 with florid disease
[9].
As early detection of antibodies may allow for earlier
treatment of anti-NMDA receptor encephalitis, which is
associated with better outcomes, we believe the present case
underscores the importance of clinicians maintaining vigilance for neurological abnormalities, which may be subtle,
in psychotic patients, and performing serological testing
according to clinical judgment [3, 10, 11]. Whether the
threshold for antibody testing should be lowered further to
include all patients presenting with first episode psychosis,
as some have recommended, will depend on the findings
of future prospective cohort studies that better assess the
prevalence of anti-NMDA receptor antibodies in this patient
population [4, 12].
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